METHODS An independent data coordinating center randomly allocated patients in a 2:1 ratio to receive CDCs or standard care. For patients assigned to receive CDCs, autologous cells grown from endomyocardial biopsy specimens were infused into the infarctrelated artery 1$5-3 months after myocardial infarction. The primary endpoint was proportion of patients at 6 months who died due to ventricular tachycardia, ventricular fibrillation, or sudden unexpected death, or had myocardial infarction after cell infusion, new cardiac tumor formation on MRI, or a major adverse cardiac event. We also assessed preliminary efficacy endpoints on MRI by 6 months. Between May 1, 2009, and Dec 30, 2014 , we randomly allocated 31 eligible participants of whom 25 were included in a perprotocol analysis. Mean baseline left ventricular ejection fraction (LVEF) was 39% (SD 12) and scar occupied 24% (10) of left ventricular mass. Biopsy samples yielded prescribed cell doses within 36 days (SD 6). No complications were reported within 24 h of CDC infusion. By 6 months, no patients had died, developed cardiac tumors, or MACE in either group. Four patients (24%) in the CDC group had serious adverse events compared with one control (13%; p¼1.00). Compared with controls at 6 months, MRI analysis of patients treated with CDCs showed reductions in scar mass (p¼0.001), increases in viable heart mass (p¼0.01) and regional contractility (p¼0.02), and regional systolic wall thickening (p¼0.015). However, changes in end-diastolic volume, end-systolic volume, and LVEF did not differ between groups by 6 months.
RESULTS
CONCLUSIONS Intracoronary infusion of autologous CDCs after myocardial infarction is safe and effective, warranting the expansion of such therapy to phase 2 study.
GW26-e1045 ITRAQ-Based Quantitative Proteomic Analysis of Heart in a Rat Model of Exhaustive Training
Haiyan Liu, Xuebin Cao No. 252 Hospital of PLA OBJECTIVES To explore the presence of informative protein biomarkers in the rat cardiac between the health group and exhausting group, The purpose of this study is to understand the difference in protein expression patterns between health and after exhaustive swimming and to evaluate the protein contributions to exhaustive training.
METHODS 20 male SD rats (male, the weight is 200AE20g, SPF) were randomly divided two groups, health group and exhausting group. The rats of exhausting group were swimming in the artificial pond, get the swimming method result in a model of Single Bout of Exhaustive Swimming in Rats. After exhaustive swimming the hearts were collected immediately. We mainly adopted advanced 8-plex ITRAQ coupled with 2D LC-MS/MS technology for proteomics.
RESULTS Analysis of proteomic data found that 122 proteins were identified with quantitative information between the two groups, of with the expression level of 69 proteins had significant differences at least, compared with the health group(ratio＞1.2 or ＜0.7, and P ＜ 0.05) ,of which 50 proteins were up-regulated, 19 proteins downregulated.
CONCLUSIONS This study provided a global view of potential mechanisms and potential biomarkers of heart, and demonstrated that iTRAQ combined with 2D LC-MS/MS quantitative proteomics is a powerful tool for biomarker discovery.
GW26-e1069
Exendin-4, An Gulcagon-like Peptide 1 Analogue, Attenuates Cardiomyocyte Hypertrophy Via AMPK/mTOR Pathway Yue Zhou, Xin He, Yiyi Huang, Yili Chen, Jiangui He Department of Cardiology, The First Affliated Hospital of Sun Yat-sen University OBJECTIVES Cardiac hypertrophy is the pathological basis of the development of various cardiovascular diseases and is a major independent risk factor of cardiovascular morbidity and mortality. Glucagon-like peptide 1 (GLP-1), an incretin peptide released from the intestine, exerts various cardioprotective actions and is proved to contribute in the regulation of cardiac functions. However, the role of Exendin-4, a stable GLP-1 analogue, in the cardiac hypertrophy remains unclear.
METHODS 1. Primary neonatal ventricular cardiomyocytes were cultured to establish the model of cardiomyocyte hypertrophy induced by phenylephrine (PE).
2. RNA isolation and quantitative real-time PCR (q-PCR) were performed to evaluate the transcriptional level of hypertrophic markers such as ANP BNP and beta-MHC.
3. Western Blotting was carried out to observe the change of the signaling pathway proteins levels.
4. The cardiomyocyte morphological change was manifested by Immunofluorescence staining and measurement of the cell surface area.
RESULTS
Our study demonstrated that exendin-4 attenuated cardiac hypertrophy induced by phenylephrine (PE), manifested by decreased hypertrophic markers such as ANP, BNP, beta-MHC and cell surface. Phosphorylated extracellular signal regulated protein kinase (phospho-ERK1/2) and phosphor-p38 mitogen-activated protein kinase (MAPK) protein levels didn't change in the team treated by exendin-4 and PE. In addition, we discovered that exendin (9-39), a GLP-1 receptor antagonist, can remove the anti-hypertrophic effect of exendin-4, evidently. Moreover, we showed that the anti-hypertrophic effect of exendin-4 was also significantly reversed by compound C, an AMPK inhibitor, and rapamycin, a selective blocker of mTOR.
CONCLUSIONS These results demonstrate that exendin-4 inhibit cardiac hypertrophy induced by PE via AMPK/mTOR pathway.
GW26-e1380
Vascular Adventitia Calcification and its Underlying Mechanism Na Li, Wenli Cheng China-Japan Friendship Hospital OBJECTIVES Previous research on vascular calcification has mainly focused on the vascular intima and media. However, we show here that vascular calcification may also occur in the adventitia as well. The purpose of this work is to help elucidate the pathogenic mechanisms underlying vascular calcification.
METHODS Mice were fed high fat diets (HFD) for 48 weeks, observing calcified lesions. Also included in this study were human subjects aged 60 years and older that had died of coronary heart disease, heart failure or renal failure, observing calcified lesions. Explant culture of fibroblasts, the primary cell type comprising the adventitia, was 
